Detalhe da pesquisa
1.
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Blood
; 143(7): 582-591, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971194
2.
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol
; 201(5): 897-904, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626914
3.
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Blood
; 138(17): 1535-1539, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289017
4.
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Haematologica
; 107(5): 1163-1171, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162182
5.
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Br J Haematol
; 192(3): 542-550, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207010
6.
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Am J Hematol
; 95(4): 372-378, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868242
7.
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Br J Haematol
; 195(3): 466-468, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34355802
8.
Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma.
Am J Hematol
; 96(10): E390-E392, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34260089
9.
Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia.
Am J Hematol
; 96(7): E250-E253, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33819355
10.
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Am J Hematol
; 95(4): E95-E98, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943341
11.
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib.
EJHaem
; 3(3): 927-929, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051045
12.
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Blood Adv
; 6(3): 1015-1024, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965304
13.
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
Blood Adv
; 6(11): 3332-3338, 2022 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35255496
14.
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Leukemia
; 36(2): 532-539, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531537
15.
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
J Clin Oncol
; 40(1): 63-71, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793256
16.
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Blood Adv
; 4(16): 3952-3959, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822482
17.
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials.
Hemasphere
; 4(3): e363, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32647793
18.
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Leuk Lymphoma
; 61(6): 1388-1394, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31992103
19.
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
Blood Adv
; 8(9): 2133-2137, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237078
20.
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia.
Hemasphere
; 5(8): e624, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34291197